The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in many cancer cells. However, a significant proportion of tumours are TRAIL-resistant erecting a major hurdle for a successful TRAIL-based treatment regimen in the future. In this context, it would be a major advantage to be able to identify the tumours that respond to TRAIL. The existence of two apoptosis-inducing receptors (TRAIL-R1 and TRAIL-R2) and two receptors that cannot transmit an apoptotic signal and have an inhibitory function (TRAIL-R3 and TRAIL-R4) make TRAIL signalling complicated. We analysed the surface expression of all four membrane-bound TRAIL receptors in cancer cell lines of various origin and primary cancer and normal cells and found a good correlation between TRAIL-sensitivity and the expression of TRAIL-R1 alone, but an even better correlation when a ratio of TRAIL-R1/TRAIL-R3+TRAIL-R4 was analysed. Experimental overexpression of TRAIL-R1 alone or in combination with TRAIL-R4 in PANC-1 cells confirmed our correlation results. Similar to the surface expression-apoptosis correlation analysis we found a high correlation between TRAIL-sensitivity and the mRNA level ratio of TRAIL-R1/TRAIL-R3+TRAIL-R4. A value of <0.85 for the ratio predicted TRAIL resistance in both protein and RNA analysis. Hence, TRAIL receptor RNA expression analysis by real-time PCR might be a feasible approach to predict possible TRAIL-responses in individual tumour samples.

Introduction

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL, also known as Apo-2L) is a member of the tumour necrosis factor family of cytokines and can selectively induce apoptosis in many cancer cells but not in most normal cells and has been proposed as a potential anti-tumour agent (1-5). TRAIL can bind to four membrane-bound death receptors (TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4, also known as DR4, DR5, DcR1 and DcR2, respectively). Both TRAIL-R1 and TRAIL-R2 contain a conserved cytoplasmic region called the death-domain that is required for TRAIL induced apoptosis (1,6,7). Upon activation of TRAIL-R1 and TRAIL-R2 the adaptor protein Fas-associated death domain (FADD) is recruited to the receptors, which, along with procaspase-8, forms the death-inducing signalling complex (DISC) (8). Active caspase-8, the apical caspase in death receptor-induced apoptosis, can then activate effector caspases, such as caspase-3, which in turn cleave many cellular substrates resulting in the biochemical and morphological features characteristic of apoptosis (9,10). However, TRAIL-R3 lacks an intracellular domain and TRAIL-R4 only contains a truncated death-domain. Thus, TRAIL-R3 and TRAIL-R4 may protect cells from TRAIL-induced apoptosis by acting as decoy receptors (6,11).

While TRAIL has shown remarkable promise as an anticancer agent, a significant fraction of tumour cells display TRAIL resistance (12-17). Different explanations have been suggested for this resistance. One hypothesis suggests the presence of decoy receptors (TRAIL-R3 and TRAIL-R4) that compete for binding to TRAIL (11,18). The internal signalling pathway causing apoptosis after TRAIL treatment has been studied in detail, but the specific functions of the different TRAIL receptors on the surface of cancer cells and possible correlations with TRAIL responses are far less clear. Several studies (19-24) suggest that regulation of TRAIL-induced apoptosis is dependent on the expression of its various receptors. Therefore, the understanding of the regulation and function of each receptor during tumour progression is a prerequisite for the therapeutic application of TRAIL and might help to predict TRAIL responses of individual tumours, allowing for the more efficient use of TRAIL in clinical trials and beyond.

In the present study, we found a high correlation of the expression level ratio of TRAIL-R1/TRAIL-R3+TRAIL-R4 to TRAIL sensitivity. Because of this high correlation of the TRAIL receptor expression ratio and apoptosis, we propose this ratio as a potentially useful marker for predicting TRAIL responsiveness of tumours.
Materials and methods

Reagents and cell lines. All reagents were purchased from Sigma (St. Louis, MO) unless otherwise stated. Human soluble recombinant TRAIL was purchased from R&D Systems (Minneapolis, MN). The human cell lines PANCl-1, Hek293 and HeLa were maintained in Dulbecco's modified Eagle's medium (DMEM). The cell line Caki-2, A549 and DLD-1 were cultured in RPMI-1640 medium. Caco-2 and the HCT116 were cultured in McCoy's medium. Media were supplemented with 10% fetal calf serum (FCS), 200 μg/ml penicillin (P) and 200 μg/ml streptomycin (S). FCS and P/S were purchased from Biochrom (Berlin, Germany). All cell lines were cultured at 37°C and 5% CO₂. Colorectal carcinoma primary cells were collected from patients during surgery from University Hospital Galway. Samples were dissected into 1x1x1 mm pieces, immersed in a 10-fold volume of RPMI-1640 containing 1.5 mg/ml collagenase, 5% FCS and antibiotics and then incubated at 37°C overnight. The suspension containing released cells was then centrifuged at 150 x g for 5 min. The precipitated cells were resuspended in culture medium [RPMI-1640, 25 mM Hepes, 5% FCS, 50 nM hydrocortisone, 20 μg/ml insulin, 10 μg/ml transferrin, 25 nM sodium selenite, 1 ng/ml epidermal growth factor (EGF), 10 μM ethanolamine, 10 μM phosphorylethanolamine, 100 pM triiodothyronine and 0.5 mM sodium pyruvate] and seeded into collagen-coated culture flasks. MSCs were obtained through the Regenerative Medicine Institute at the National University of Ireland, Galway and grown, characterised and maintained, as previously described (25).

Measurement of apoptosis. For the detection of apoptotic cell death, standard DNA fragmentation assays according to Nicoletti et al (26) and Braeuer et al (27) were used. Untreated cells were taken as reference to calculate specific apoptosis by subtraction of the basal apoptosis values from the levels of treated cells.

Determination of the surface TRAIL receptor expression. TRAIL-R1 (HS 101), TRAIL-R2 (HS 201), TRAIL-R3 (HS 301) and TRAIL-R4 (HS 402) monoclonal antibodies (Alexis, Lausen, Switzerland) were used for FACS analyses of surface receptor expression, as previously described (28). Unspecific murine IgG1 was used as control for unspecific staining (isotype control).

Quantitative real-time PCR assays. Gene quantification was performed with a LightCycler (Roche Diagnostics, Mannheim, Germany) real-time PCR system. Total RNA was prepared from subconfluent cells using the RNAeasy mini kit from Qiagen (Hilden, Germany). The primer-probe sets were designed with the GeneFisher software. Porphobilinogen Deaminase (PBGD) real-time PCR was used to normalise TRAIL-receptor data.

Statistical analyses. If not stated, three independent experiments were performed in triplicate. Experimental values are expressed as mean value ± standard error (SE). Linear regression analyses were performed to examine the correlation between the resistance to TRAIL and the expression of the TRAIL receptors. The correlation is expressed as R². For significance analyses Student’s t-tests, were used and p<0.05 was considered significant and p<0.001 as highly significant.

Results

TRAIL responsiveness varies among different tumour cell lines and primary (cancer) cells. Solid tumour cell lines of various tissue origins including colon cancer cell lines (HCT116, DLD-1, Caco-2), renal cancer cells (Caki-2), non-small lung cancer cells (A549), cervical cancer cells (HeLa) and pancreatic cancer cells (PANC-1) were used in this study. Furthermore, primary colon carcinoma cells (FMC), human mesenchymal stem cells (MSCs), human primary fibroblasts and transformed embryonic kidney cells (HeK293) were analysed. To evaluate the cell killing effect of TRAIL on these cells, they were treated with various concentrations (2, 5 and 10 ng/ml) of soluble recombinant TRAIL for 24 h, after which the apoptotic response was measured (Fig. 1). Two cell lines (Caki-2, DLD-1) were highly sensitive to TRAIL-mediated cell death with ≥70% of the cells killed when challenged with 10 ng/ml of TRAIL. HeLa and HCT116 cells were sensitive with ~50% of the cells killed. Hek293 cells were defined as moderate sensitive with apoptosis rates of 10-20%. The other cell types (FMC, hMSC, fibroblasts, Caco-2, PANC-1, A549) were resistant to TRAIL-induced apoptosis. To see if the different TRAIL responsiveness could be attributed to their TRAIL-receptor expression profiles, we analysed the protein expression of the four membrane-bound TRAIL receptors.

TRAIL responsiveness is correlated to the ratio of expression levels of TRAIL-1 and the sum of TRAIL-R3 and TRAIL-R4. In order to determine whether there is a correlation between TRAIL responsiveness and the expression levels of the four TRAIL-receptors, the surface protein expression levels of the four membrane-bound TRAIL receptors were analysed (Fig. 2A). Surface protein levels were determined by FACS measurements after staining with specific TRAIL receptor antibodies and a PE-labelled secondary antibody (Fig. 2A).
We found varying TRAIL-receptor expression profiles, but TRAIL sensitivity seemed to correlate with the expression of the apoptosis-activating receptors TRAIL-R1, as the most sensitive cell lines (DLD-1 and Caki-2) had the highest expression levels of this receptor and the TRAIL-resistant cell lines such as PANC-1 showed very low expression levels of TRAIL-R1. However, A549 and Hek293 cells appeared to be outliers in this regard. Both cell lines harboured high TRAIL-R1, but were either TRAIL-resistant (A549) or showed only moderate TRAIL responsiveness (Hek293). To analyse this correlation in more detail we performed a regression analysis between the expression level of TRAIL-R1 and TRAIL responsiveness (10 ng/ml TRAIL) of the cell lines tested (Fig. 2B). Despite the two outliers regression analysis confirmed a good correlation of TRAIL-R1 expression level with TRAIL responsiveness (Fig. 2B). Next, we tested whether inclusion of the decoy receptors would improve our regression analysis. Indeed, we arrived at an even higher correlation coefficient ($R^2$) using the ratio of TRAIL-R1 and the sum of the expression levels as expressed in MFI ratios of TRAIL-R3 and TRAIL-R4 (Fig. 2C). Overall, a ratio of ≤0.85 for the MFI of TRAIL-R1 divided by the sum of the MFIs of TRAIL-R3 +TRAIL-R4 was found to be predictive for TRAIL resistance. Hence, the expression levels of the apoptosis-activating receptor TRAIL-R1 in relation to TRAIL-R3 and TRAIL-R4 appears to be predictive for the TRAIL responsiveness of cancer as well as normal cells.

*Overexpression of TRAIL-R1 and TRAIL-R4 in PANC-1 cells.* In order to confirm the correlation between the TRAIL sensitivity and the ratio of TRAIL receptor expression levels, we generated stable PANC-1 cell lines that overexpressed...
either TRAIL-R1 alone or together with TRAIL-R4. Protein expression of the TRAIL receptors was measured by FACS and we established two independent clones (C1, C2) that overexpressed TRAIL-R1 to different levels (Fig. 3A). C2 was used to concurrently overexpress TRAIL-R1 and TRAIL-R4 resulting in clone 3 (C3) (Fig. 3A). Subsequently, we treated these clones as well as parental PANC-1 cells with TRAIL and measured apoptosis. The apoptosis assay revealed that C1 and C2 were TRAIL-sensitive with apoptosis rates of 35% (C1) to 60% (C2) (Fig. 3B). In C3 apoptosis was markedly reduced (45%) as compared to its parental clone C2 (60%) owing to the moderate overexpression of TRAIL-R4 in C3. Next, we wanted to test whether these experimentally generated PANC-1 cell clones would also fit our correlation model. The correlation diagram including our original cell lines and primary cells as well as the three PANC-1 clones, C1, C2 and C3 confirm the relationship between TRAIL responsiveness and the expression levels of the TRAIL-R1, TRAIL-R3 and
TRAIL-R4 (Fig. 3C). Hence, it appears possible to use this model to predict TRAIL sensitivity.

In a clinical setting it would probably be easier and more reliable to prepare RNA from tissue biopsies than to perform tissue staining with four different TRAIL receptor antibodies, while FACS analysis is unlikely to be a feasible option. Moreover, real-time PCR procedures can be automated and give rise to quantitative data. Therefore, we were interested in determining mRNA expression levels of the TRAIL receptors and compare them to surface protein expression levels.

**Determination of mRNA expression levels of TRAIL receptors by real-time PCR.** Overall, the mRNA expression levels, as measured by real-time PCR, of the four TRAIL receptors were comparable to the surface protein expression levels (Fig. 4A). Again there was a good correlation of TRAIL-R1 expression and TRAIL sensitivity (Fig. 4B), but the ratio of TRAIL-R1/(TRAIL-R3+TRAIL-R4) yielded an even better correlation coefficient (Fig 4C). Again, a factor of <0.85 for MFI TRAIL-R1/MFI TRAIL-R3+MFI TRAIL-R4 indicated TRAIL resistance. We conclude that TRAIL responsiveness is highly correlated to the expression of TRAIL-R1 as well as TRAIL-R3 and TRAIL-R4 and that quantitative RNA analysis by real-time PCR is a suitable method to measure and calculate a coefficient (TRAIL-R1/TRAIL-R3+TRAIL-R4) that can predict responsiveness to TRAIL.

**Discussion**

Resistance to TRAIL-induced apoptosis can occur at different levels in the TRAIL signalling cascade. One important factor that can lead to TRAIL resistance is the impaired or dysfunctional expression of TRAIL receptors. For example a
expression by real-time PCR was as good as TRAIL-receptor treatment. As we found that measuring TRAIL-receptor receptor expression profile is not the only determining determining factor for TRAIL responsiveness. Plotting our protecting TRAIL receptors (TRAIL-R3 and TRAIL-R4) is an analysis of TRAIL-receptor expression levels and TRAIL-to TRAIL cells to be <0.85. While it is clear that the TRAIL-cancer cell lines, primary colon carcinoma, fibroblastic cells of tumors. J Exp Med 190: 891-894, 1999.


39. Lincz LF, Yeh TX and Spencer A: TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15: 1650-1657, 2001.
